Acasti Pharma Inc. engages in the research, development, and commercialization of active pharmaceutical ingredients to treat cardiometabolic disorders. It is developing bioactive ingredients of proprietary novel omega-3 phospholipids through the pharmaceutical development pathway, which includes prescription medical foods, over-the-counter products (OTC), and prescription drugs. The company's lead prescription drug candidate, CaPre that is in Phase II clinical trial for the prevention and treatment of cardiometabolic disorders, including hypertriglyceridemia, a condition which is characterized by abnormally high levels of triglycerides. Its products also include Onemia, an omega-3 phospholipid concentrate and medical food for chronic cardiometabolic disorders. The company was incorporated in 2002 and is headquartered in Laval, Canada. Acasti Pharma Inc. is a subsidiary of Neptune Technologies and Bioressources Inc.